Advertisement
Q&A: 'Imagine if healthcare were priced to consumers'

Q&A: 'Imagine if healthcare were priced to consumers'

By Modern Healthcare  |  February 14, 2015

Mark Ganz, president and CEO of Cambia Health Solutions, a not-for-profit parent of 22 companies offering healthcare products and services, discusses how his companies are seeking to make healthcare more consumer-directed.

Lobbying peaks as rates for Medicare Advantage expected

Lobbying peaks as rates for Medicare Advantage expected

By Bob Herman  |  February 14, 2015

Health insurance lobbyists are sharpening their knives this week in preparation for the CMS' scheduled announcement of preliminary 2016 Medicare Advantage payment rates after the markets close Friday.

Why can't insurers publish accurate provider directories?

By Darius Tahir  |  December 13, 2014

As insurers face growing criticism for giving consumers inaccurate information about their provider networks, some experts are asking whether it's really that hard to maintain an accurate provider directory.

Harvard Pilgrim CEO talks about narrrow networks and reform

Harvard Pilgrim CEO talks about narrrow networks and reform

By Modern Healthcare  |  November 22, 2014

Eric Schultz, CEO of Wellesley, Mass.-based Harvard Pilgrim Health Care, discusses his organization's experience with the Obamacare insurance exchanges, narrow provider networks, re-entering the Medicare Advantage program, and his views on the expansion of Partners HealthCare in Massachusetts.

Reform Update: Partisan standoff looms over crucial risk-corridor payments

Reform Update: Partisan standoff looms over crucial risk-corridor payments

By Paul Demko  |  October 24, 2014

A big fight could be brewing over Obamacare's risk-corridor program. Insurers are relying on the program to protect them from major losses if their exchange customers end up being sicker and more costly than anticipated. But Republicans—most notably Sen. Marco Rubio (R-Fla.), a likely 2016...

New hepatitis C drug costs nearly $100,000

By Paul Demko  |  October 11, 2014

A second potential blockbuster drug from Gilead Sciences to treat hepatitis C has been approved by the FDA. But at a cost of nearly $100,000 for a full course of treatment, it is certain to spark further debate over the pricing of specialty drugs.

Advertisement
Modern Healthcare Daily

The top stories in healthcare business every day

The Modern Healthcare Daily News App provides you with registration-free access to the top trending healthcare business news. It's the only news you need each day.